EFTR vs. CANF, CMMB, TRVN, KTTA, TENX, PULM, GRAY, LIXT, IBIO, and UPC
Should you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Can-Fite BioPharma (CANF), Chemomab Therapeutics (CMMB), Trevena (TRVN), Pasithea Therapeutics (KTTA), Tenax Therapeutics (TENX), Pulmatrix (PULM), Graybug Vision (GRAY), Lixte Biotechnology (LIXT), iBio (IBIO), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical preparations" industry.
Can-Fite BioPharma (NYSE:CANF) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
Can-Fite BioPharma has higher earnings, but lower revenue than eFFECTOR Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Can-Fite BioPharma had 2 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 0 mentions for eFFECTOR Therapeutics. eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.
21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 8.4% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Can-Fite BioPharma currently has a consensus target price of $15.00, suggesting a potential upside of 661.42%. eFFECTOR Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 1,248.31%. Given Can-Fite BioPharma's higher possible upside, analysts plainly believe eFFECTOR Therapeutics is more favorable than Can-Fite BioPharma.
eFFECTOR Therapeutics received 22 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 2.56% of users gave Can-Fite BioPharma an outperform vote.
Can-Fite BioPharma has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
eFFECTOR Therapeutics has a net margin of 0.00% compared to eFFECTOR Therapeutics' net margin of -1,027.46%. Can-Fite BioPharma's return on equity of 0.00% beat eFFECTOR Therapeutics' return on equity.
Summary
eFFECTOR Therapeutics beats Can-Fite BioPharma on 10 of the 16 factors compared between the two stocks.
Get eFFECTOR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
eFFECTOR Therapeutics Competitors List
Related Companies and Tools
